Ranbaxy Pharmaceuticals Inc, (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has been chosen to present its poster presentation, "An Assessment of the Pharmacokinetic Profile of Metformin Hydrochloride Oral Solution (100 mg/mL) (MOS) under Fasting, Low-Fat, and High Fat Meal Conditions," at the American Association of Clinical Endocrinologists' (AACE) 13th Annual Meeting and Clinical Congress on May 1, 2004.

Ranbaxy's research shows no diminution of bioavailability of metformin in adults under either condition.

The study was conducted as an open-label, single-dose study comparing the single-dose bioavailability of metformin oral solution (100 mg/mL) (MOS) under fasting and fed states, a company release said.

Dr Kiran Marthak, vice- president, Medical Affairs and Clinical Research, RLL, will demonstrate the research findings that imply that the bioavailability of the MOS solution was unaffected by fasting or fed conditions in healthy adult subjects. The research team was able to arrive at this conclusion since the bioavailability of the MOS was within the 80-125 per cent FDA-acceptance criterion.

The AACE's 13th Annual Meeting and Clinical Congress focuses on presenting scientific and technological advances, as well as social, economic and political advances in endocrinology to clinical endocrinologists, doctors, registered nurses and pharmacists.